Skip to main content

Advertisement

Table 2 Main results of historical comparison (simeprevir + PegIFNα-2a + RBV vs. PegIFNα-2a + RBV)

From: Simeprevir with pegylated interferon alfa 2a plus ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a meta-analysis and historical comparison

  Number of patients with event/total number of patients (%) Relative risk (95 % CI) Risk difference (95 % CI)
  Simeprevir + PegIFNα-2a + RBV PegIFNα-2a + RBV
Efficacy
SVR24 (random effects) 77/106 (72.6 %) 104/369 (28.2 %) 2.58 (2.11; 3.15) 0.45 (0.34; 0.55)
SVR24 (fixed effects) 364/1313 (27.7 %) 2.62 (2.27; 3.03) 0.45 (0.36; 0.54)
Safety
At least one AEa 103/106 (97.2 %) 396/410 (96.6 %) 1.01 (0.97; 1.04) 0.01 (−0.04; 0.05)
At least one SAEa 11/106 (10.4 %) 67/407 (16.5 %) 0.63 (0.35; 1.15) −0.06 (−0.14; 0.01)
AEs leading to discontinuationb 5/106 (4.7 %) 21/135 (15.6 %) 0.30 (0.12; 0.78) −0.11 (−0.19; −0.03)
Anemia AEs (random effects) 35/106 (33.0 %) 58/202 (28.7 %) 1.15 (0.81; 1.63) 0.04 (−0.07; 0.16)
Anemia AEs (fixed effects) 124/418 (29.7 %) 1.11 (0.82; 1.52) 0.03 (−0.07; 0.14)
Psychiatric disorders AEsc 63/106 (59.4 %) 3/10 (30.0 %) 1.98 (0.76; 5.17) 0.29 (−0.06; 0.65)
  1. aNo difference between random and fixed effects models
  2. bResults for PegIFNα-2a + RBV from Torres-Cornejo 2014 [18]
  3. cResults for PegIFNα-2a + RBV from Murphy 2011 [15]
  4. CI confidence interval, SVR24 sustained virologic response 24 weeks after planned end of treatment, AE adverse event, SAE serious adverse event, RBV ribavirin, PegIFNα-2a peginterferon-alpha-2a